Pharmaceutical sponsor
Mabwell (Shanghai) Bioscience Co., Ltd. Clinical Trials
Studies where Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 19GI Cancers
First-in-human Study of 7MW4911 in GI Cancer
This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
- Trial name
- NCT07216560
- Testing
- 7MW4911
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Triple Negative Breast Cancer
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
- Trial name
- NCT06908928
- Testing
- bulumtatug fuvedotin
- Where
- 7 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Lung Squamous Cell Carcinoma
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy
To compare the efficacy and safety of 7MW3711 versus docetaxel in patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) .
- Trial name
- NCT07831863
- Testing
- 7MW3711, Docetaxel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Scar
A Phase II Study of 9MW3811 in Patients With Pathological Scar
This is a randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of 9MW3811 in patients with pathological scar.
- Trial name
- NCT07576608
- Testing
- 9MW3811 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Locally Advanced or Metastatic Triple-negative Breast Cancer
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously…
- Trial name
- NCT07556848
- Testing
- 9MW2821, Chemotherapy
- Where
- China
- Volunteers
- 356 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Solid Tumor
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.
- Trial name
- NCT07466160
- Testing
- 7MW3711, JS207, Cisplatin
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Urothelial Carcinoma
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
- Trial name
- NCT07314723
- Testing
- 9MW2821, Toripalimab Injection
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Solid Tumors
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.
- Trial name
- NCT07265622
- Testing
- 7MW4911
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Chronic Obstructive Pulmonary Disease COPD
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety of 9MW1911 in patients with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT07292714
- Testing
- 9MW1911
- Where
- 51 sites in China
- Volunteers
- 360 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Polycythemia Vera
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.
- Trial name
- NCT06752746
- Testing
- 9MW3011
- Where
- 6 sites in China
- Volunteers
- 108 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.